BPC-157: A Research Reference
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular weight ~1,419 Da). Originally identified as a fragment of a larger endogenous gastric protein, it has appeared in preclinical pharmacology research since the early 1990s, primarily originating from research groups at the University of Zagreb.
BPC-157 is catalogued in the scientific literature under several designations: BPC-157, BPC 157, pentadecapeptide BPC 157, PL 14736, and PLD-116. It has been studied as an experimental agent in Phase II inflammatory bowel disease trials and is commonly used as a reference compound in pharmacological research.
One property that distinguishes it from many short peptides is its stability in human gastric juice — studies indicate it remains intact for over 24 hours in this environment — making it a useful research model for investigating orally administered peptidergic agents.
This article is a research reference only. BPC-157 is not an approved drug, is not intended for human or veterinary use, and is sold by Sirius Molecules strictly for in vitro and preclinical laboratory research. See the Research Use Only (RUO) disclaimer at the end of this page.
Preclinical Research Overview
Based on articles retrieved from PubMed, the peer-reviewed research on BPC-157 spans several broad areas: musculoskeletal tissue repair, gastrointestinal mucosal protection, angiogenesis, and neurological function via the brain-gut axis. The overwhelming majority of published studies are animal models (rodent, primarily rat) or in vitro cell culture experiments.
A 2025 systematic review published in HSS Journal (Vasireddi et al.) identified 544 articles from 1993 to 2024 and included 36 studies after screening — 35 preclinical, 1 retrospective clinical. The review noted that preclinical findings consistently report improvements in functional and structural outcomes across tissue types, and that BPC-157 is metabolized in the liver with a half-life under 30 minutes, with renal clearance (DOI: 10.1177/15563316251355551).
Research Area 1: Musculoskeletal Repair
The largest body of BPC-157 preclinical literature addresses soft-tissue repair — tendons, ligaments, and muscle.
Tendon Research
A widely cited study by Staresinic et al. (2003, Journal of Orthopaedic Research) examined Achilles tendon transection in rats. Animals treated with BPC-157 showed consistent improvements across biomechanical measures (load to failure, Young’s modulus of elasticity), functional assessments (Achilles functional index), and histological findings (increased fibroblast formation, superior collagen organization, reduced granulocyte infiltration). The researchers also demonstrated in vitro that BPC-157 opposed the growth-inhibiting effects of 4-hydroxynonenal on cultured tendocytes (DOI: 10.1016/S0736-0266(03)00110-4).
A 2026 narrative review by Mayfield et al. (American Journal of Sports Medicine, Keck School of Medicine of USC) reviewed BPC-157 alongside other injectable peptides of interest to orthopaedic medicine. The authors noted that BPC-157 demonstrates potential in tendon and muscle repair in animal models but that human clinical data remain limited, with a single case series the only available human musculoskeletal data at the time of review (DOI: 10.1177/03635465251357593).
Ligament Research
Cerovecki et al. (2010, Journal of Orthopaedic Research) investigated medial collateral ligament (MCL) healing in rats following surgical transection. BPC-157 was administered via three routes — intraperitoneal injection, topical cream, and oral (in drinking water) — with all three routes producing consistent functional, biomechanical, macroscopic, and histological improvements at 90 days. The authors noted the compound’s effectiveness across multiple administration routes as a point of pharmacological interest (DOI: 10.1002/jor.21107).
The 2025 systematic review (Vasireddi et al.) further summarized preclinical evidence suggesting BPC-157 enhances growth hormone receptor expression and activates pathways involved in cell growth and angiogenesis, while modulating inflammatory cytokine activity in musculoskeletal injury models (DOI: 10.1177/15563316251355551).
Research Area 2: Gastrointestinal and Cytoprotective Research
BPC-157’s origin as a gastric-protein fragment makes the gastrointestinal context central to its research history.
Sikiric et al. (1997, Digestive Diseases and Sciences, University of Zagreb) conducted early mechanistic studies investigating BPC-157’s interactions with adrenergic and dopaminergic systems in mucosal protection under restraint stress. The study mapped how different receptor-pathway manipulations affected BPC-157’s gastroprotective effect, identifying complex interactions with alpha-adrenergic and central dopaminergic systems as contributing factors (DOI: 10.1023/a:1018880000644).
Sikiric et al. (2024, Inflammopharmacology) provided a comprehensive review of BPC-157 in the context of cytoprotection and organoprotection — the broader concept that a gastric-origin compound may exert protective effects across multiple organ systems. The review covers GI mucosal maintenance, vascular recovery, endothelium protection, and the compound’s modulation of the nitric oxide system (DOI: 10.1007/s10787-024-01499-8).
Research Area 3: Angiogenesis and Tissue Repair
A recurring finding across BPC-157 research is its apparent influence on angiogenesis — the formation of new blood vessels — and granulation tissue formation.
Sikiric et al. (1999, Journal of Physiology, Paris) used subcutaneous sponge implants in rats to measure new vessel formation and granulation tissue. BPC-157-treated animals showed marked increases in newly formed endothelial spaces at both 3 and 7 days post-implant. Unlike H2-blockers, BPC-157 also stimulated granulation tissue formation, suggesting distinct angiogenic activity (DOI: 10.1016/s0928-4257(99)00123-0).
A 2026 review by Yuan et al. (International Journal of Molecular Sciences, with authors from Harvard, Johns Hopkins, and Brown University affiliations) synthesized evidence for BPC-157’s proposed mechanisms: supporting angiogenesis, collagen synthesis, and fibroblast activity; modulating nitric oxide pathways; reducing inflammatory cytokine levels; and improving microvascular integrity across GI, musculoskeletal, and other tissue types (DOI: 10.3390/ijms27062876).
Research Area 4: Neurological Function and the Brain-Gut Axis
A body of preclinical literature examines BPC-157 in the context of the brain-gut axis — the bidirectional communication network connecting the enteric and central nervous systems.
Sikiric et al. (2016, Current Neuropharmacology) reviewed the compound’s neurological effects, reporting that BPC-157 modulates serotonergic and dopaminergic neurotransmitter systems; demonstrates neuroprotective effects in traumatic brain injury and spinal cord compression models; supports peripheral nerve regeneration following transection; and attenuates encephalopathies induced by NSAIDs and cuprizone in rodent models. The authors proposed BPC-157 as a potential bridge between gastrointestinal and central nervous system pharmacology (DOI: 10.2174/1570159×13666160502153022).
Klicek et al. (2013, Journal of Physiology and Pharmacology, University of Zagreb) reported parallel findings in a study combining colitis and cuprizone-induced brain injury models. BPC-157 treatment was associated with efficient healing in cysteamine-induced colitis and colon-colon anastomosis, while simultaneously reducing nerve damage across multiple brain regions in the cuprizone cohort — notably in the corpus callosum, laterodorsal thalamus, and anterior horn motor neurons.
Physical Characteristics and Stability
| Property | Value |
|---|---|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Amino acids | 15 |
| Molecular weight | ~1,419 Da |
| Appearance (lyophilized) | White to off-white powder |
| Gastric juice stability | Stable >24 hours in human gastric juice |
| Metabolic half-life | <30 minutes (hepatic metabolism, renal clearance) |
Lyophilized BPC-157 reference material should be stored under recommended conditions and protected from moisture, light, and repeated freeze-thaw cycles. For unopened vial storage and handling guidelines applicable to lyophilized research peptides generally, see our Storage & Stability of Lyophilized Reference Compounds guide.
Quality and COA Considerations
As with all peptide reference compounds, purity documentation is essential when sourcing BPC-157 for research. Key parameters to verify on a Certificate of Analysis (COA):
- Purity (HPLC): Reverse-phase HPLC purity. Look for the method used (UV detection wavelength, column type) and whether net peptide content is reported separately from gross purity. For a full explanation, see Peptide Purity vs. Net Peptide Content.
- Identity (Mass Spectrometry): Molecular weight confirmation by ESI-MS or MALDI-TOF confirms the correct sequence and rules out truncated or scrambled peptides.
- Counterion content: TFA (trifluoroacetic acid) is commonly used in HPLC purification and is present in most research-grade peptides as a salt counterion. Higher TFA content reduces net peptide per unit mass.
- Endotoxin: Relevant for cell-based or in vivo research. LAL or rFC endotoxin testing should be specified if your application requires low-endotoxin material.
- Lot-specific testing: Sirius Molecules provides Accumark-verified, cryptographically signed COAs for every batch. To verify your lot, visit our COA Verification page.
Research Use Only — Regulatory Notice
BPC-157 is sold by Sirius Molecules strictly for in vitro laboratory research and preclinical studies. It is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body for human or veterinary therapeutic use. It is not a drug, supplement, or food product, and must not be administered to humans or animals outside of a licensed research setting.
This article is provided for informational and educational purposes to support the research community. Nothing in this content constitutes medical advice, a treatment recommendation, or a claim of efficacy or safety in any human or veterinary application. Researchers are responsible for compliance with all applicable institutional, local, state, and federal regulations governing the use of research compounds.
Sources cited from PubMed. DOI links are provided for each referenced study.
